Besins Healthcare
 | The topic of this article may not meet Wikipedia's notability guidelines for companies and organizations. (February 2013) |
Besins Healthcare is a privately held, fifth-generation family-owned multinational pharmaceutical company headquartered in Monaco. Founded in 1885 in Paris, Besins Healthcare focuses on transdermal delivery technology treatments and has products available in 100 countries.
The company specializes in Women’s and Men’s Health and is manufacturing and developing drugs for the treatment of gynecological, fertility, and obstetrical conditions as well as androgen deficiencies.[1] Besins Healthcare has three subsidiaries: BHR Pharma, LLC, Ascend Therapeutics and Pure Matters.
Ascend Therapeutics is involved in the research and development of transdermal drugs that are applied to the skin as a gel to treat chronic conditions such as severe breast pain for pre-menopausal women, and low testosterone levels for older men.[1]
Besins Healthcare global research and development is conducted out of BHR Pharma, and LLC. BHR Pharma is in the last stage of human testing of a potential progesterone-based treatment (BHR-100) for severe traumatic brain injury (TBI).[2][3] The Food and Drug Administration has promised to fast-track the approval process for BHR-100 if the findings are positive.[4] The drug is one of four compounds in late-stage development to combat TBI, and is the only one expected to reach the market before 2019.[5]
Controversy[edit]
AG Rosenblum Sues Pharmaceutical Giants AbbVie and Besins[edit]
In November 2022, Oregon Attorney General Ellen Rosenblum sued AbbVie, Abbott Laboratories, Unimed Pharmaceuticals. The lawsuit alleges that the four pharmaceutical companies, which held the exclusive patent for brand-name AndroGel, filed baseless lawsuits to monopolize the market and prevent competitors from entering, which resulted in much higher prices.[6]
Federal Trade Commission v. AbbVie[edit]
The FTC filed a complaint in federal district court in September 2014 charging that AbbVie Inc. and its partner Besins Healthcare Inc. illegally blocked American consumers’ access to lower-cost alternatives to Androgel by filing baseless patent infringement lawsuits against potential generic competitors. In a June 2018 decision, the U.S. District Court for the Eastern District of Pennsylvania ruled that sham litigation was used to create a monopoly.[7]
References[edit]
- ^ a b Flandez, Ramon (July 5, 2004). "For Ascend Therapeutics, Success Is Only Skin Deep". The Washington Post. Retrieved June 19, 2012.
- ^ "Efficacy and Safety Study of Intravenous Progesterone in Patients With Severe Traumatic Brain Injury (SyNAPSe)". ClinicalTrials.gov. June 14, 2010. Retrieved August 21, 2022.
- ^ Begley, Sharon (May 16, 2012). "Revealing brain damage from battlefield to playing field". Reuters. Archived from the original on February 16, 2013. Retrieved May 14, 2012.
- ^ Tuller, David (June 18, 2012). "A Hormonal Remedy for Brain Injuries Is Explored". The New York Times. Archived from the original on June 25, 2012. Retrieved June 19, 2011.
- ^ "TBI Research Creates Opportunities for Pharma". Drug Discovery & Development. June 1, 2012. Archived from the original on October 23, 2012. Retrieved June 19, 2012.
- ^ Nguyen, Ally (2022-11-10). "AG Rosenblum Sues Pharmaceutical Giants AbbVie and Besins". Oregon Department of Justice. Retrieved 2023-01-21.
- ^ "AbbVie Inc., et al". Federal Trade Commission. 2014-09-08. Retrieved 2023-01-21.
